Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Proyecto:
Ministerio de Ciencia e Innovación RTI2018-097267-B-100
,
Agencia Estatal de Investigación SAF2016-79381-R
,
Ministerio de Ciencia e Innovación SAF2016-81975-REDT
,
European Commission 336343
,
European Commission 819242
,
European Commission 754627
,
European Commission 721532
,
Ministerio de Economía y Competitividad SAF2015-66015-R
,
Ministerio de Ciencia e Innovación CB16-12-00228
,
Agencia Estatal de Investigación SAF2016-79847-R
,
Agencia Estatal de Investigación BFU2017-84653-P
,
Ministerio de Ciencia e Innovación SEV-2016-0644
,
Instituto de Salud Carlos III PI18-00442
,
Instituto de Salud Carlos III PI15-00339
,
Ministerio de Economía y Competitividad SAF2015-64237-R
,
Ministerio de Ciencia e Innovación SAF016-76008R